SingleBioregulators

Pielotax 20 mg oral

Pielotax (A-9) is an oral animal-derived peptide complex explored in preclinical models for renal cellular health and functional protection.

Mechanism

It is hypothesized to interact with the minor grooves of cellular DNA within renal tissues to modulate gene transcription, attenuate cellular senescence markers, and stimulate tissue repair pathways.

Dosing

Standard laboratory literature outlines an intake of 10 mg to 20 mg orally once or twice daily over a cyclical 30-day course.

Reconstitution

Pielotax is manufactured as an oral solid preparation and requires zero liquid reconstitution.

Storage

Keep oral capsules in an airtight container under cool, dark, and dry conditions away from moisture and direct sunlight.

Mix & measure Pielotax 20 mg oral

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Pielotax 20 mg oral

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration—

Draw volume—

On the syringe—

Total doses in vial: —

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Day 1 - 30 (Standard Course)	10–20 mg (1–2 capsules) once or twice daily	N/A (Oral Capsule)
Maintenance / Intermission	No administration for 3–4 months	N/A

Reconstitution Steps

1
No liquid reconstitution is required because this compound is supplied exclusively as an oral dry capsule.
2
Verify capsule integrity, physical uniformity, and batch documentation on the manufacturer packaging.
3
Do not introduce bacteriostatic water, antimicrobial solvents, or syringe hardware to the preparation.
4
Maintain the dry product in its original sealed packaging until ready for experimental study.

Supplies Needed

Peptide Vial

Provides the encapsulated oral Pielotax A-9 natural renal peptide complex.

Insulin Syringes (U-100)

Not applicable; oral capsules require no volumetric measurement or parenteral equipment.

Bacteriostatic Water

Not applicable; this solid oral preparation requires no liquid solvent.

Alcohol Swabs

Not applicable; oral capsule protocols do not involve sterile skin preparation.

Why researchers study it

Renal filtration and acute injury resilience models

Cellular senescence and SIRT-6 expression modulation

Organ-specific peptide bioregulator mapping

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Pielotax, designated in bioregulator nomenclature as A-9, is an organ-specific natural peptide extract derived from juvenile animal renal tissue. Unlike synthetically engineered short peptides with discrete amino acid sequences, it comprises a low-molecular-weight fraction containing diverse endogenous peptide chains. As part of Vladimir Khavinson's Cytomax class of geroprotective bioregulators, the preparation is designed to deliver tissue-specific regulatory fragments rather than broadly acting systemic compounds. In experimental models, the primary scientific interest focuses on its potential to influence cellular senescence, improve diuresis, and preserve renal architecture under chemical strain. In vitro and rodent studies using kidney-derived peptide fractions have shown alterations in gene expression pathways related to cell turnover and stress resilience. However, robust clinical validation in humans remains absent from formal regulatory registries, keeping this compound strictly within exploratory and academic research contexts.

References

1.Zamorskii et al., Bulletin of Experimental Biology and Medicine, 2015 — Peptides restore functional state of the kidneys during cisplatin-induced acute renal failure
2.Khavinson et al., Advances in Gerontology / Uspekhi Gerontologii, 2014 — Tripeptides slow down aging process in renal cell culture
3.Khavinson, Neuro Endocrinology Letters, 2002 — Peptides and Ageing
4.Khavinson et al., Advances in Gerontology / Uspekhi Gerontologii, 2013 — Peptide bioregulators: the new class of geroprotectors. Message 2: clinical studies results